S&CO Inc. Takes Position in United Therapeutics Corporation $UTHR

S&CO Inc. acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 1,431 shares of the biotechnology company’s stock, valued at approximately $775,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of UTHR. Geneos Wealth Management Inc. boosted its holdings in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares during the period. Jump Financial LLC purchased a new position in United Therapeutics in the 2nd quarter worth approximately $277,000. Cerity Partners LLC lifted its position in United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia lifted its position in United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total value of $4,291,515.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,356,182.60. This represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $515.03, for a total transaction of $4,892,785.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $167,097,878.29. This represents a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 443,075 shares of company stock valued at $241,508,744 in the last ninety days. 8.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on UTHR shares. Royal Bank Of Canada dropped their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $499.73 on Monday. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The stock has a 50 day simple moving average of $535.95 and a two-hundred day simple moving average of $536.15. The stock has a market cap of $21.43 billion, a P/E ratio of 17.88, a price-to-earnings-growth ratio of 1.69 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the company earned $6.41 EPS. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. Sell-side analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.